Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $7.00 price target on the stock.

A number of other research firms also recently commented on KPTI. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Monday, February 10th. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Piper Sandler raised their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Down 1.9 %

KPTI opened at $0.60 on Thursday. The firm has a market cap of $75.54 million, a P/E ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 52 week low of $0.53 and a 52 week high of $1.70. The business’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. As a group, equities analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in Karyopharm Therapeutics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after acquiring an additional 36,922 shares in the last quarter. Silverarc Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after acquiring an additional 37,524 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter worth $27,000. Two Sigma Advisers LP grew its holdings in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter worth $31,000. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).